Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | LOX | P28300 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2170231 | 0.83 | LMNA (0.42) | SMN1; SMN2LMNALOXLOXL2PTGS2 | |
| SCHEMBL1349272 | 0.79 | GLP1R (0.34) | SMN1; SMN2LMNALOXGLP1RHTR6 | |
| SCHEMBL1348689 | 0.77 | ALDH1A1 (0.38) | SMN1; SMN2LMNALOXLOXL2L3MBTL1 | |
| SCHEMBL3691082 | 0.75 | LMNA (0.55) | SMN1; SMN2LMNAL3MBTL1KMT2ATSHR | |
| SCHEMBL8658127 | 0.75 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAL3MBTL1PTGS2KMT2A | |
| SCHEMBL1346260 | 0.72 | LMNA (0.47) | SMN1; SMN2LMNATSHRALDH1A1KDM4E | |
| SCHEMBL3465468 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2ATSHRKCNH2 | |
| SCHEMBL3439355 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAPTGS2KMT2ATSHR | |
| SCHEMBL28026807 | 0.72 | LMNA (0.55) | SMN1; SMN2LMNAL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL5360302 | 0.72 | LMNA (0.78) | SMN1; SMN2LMNAL3MBTL1PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8063065-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | SMN1; SMN2 1172/4885LMNA 4848/4885LOX 3862/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | SMN1; SMN2 411/4885LMNA 3632/4885LOX 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.